{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T16:09:34Z","timestamp":1776701374293,"version":"3.51.2"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Cancer Institute","award":["R01CA244601"],"award-info":[{"award-number":["R01CA244601"]}]},{"DOI":"10.13039\/100031022","name":"Center for Cancer Research","doi-asserted-by":"crossref","award":["R01CA285391"],"award-info":[{"award-number":["R01CA285391"]}],"id":[{"id":"10.13039\/100031022","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100016350","name":"Massey Comprehensive Cancer Center, Virginia Commonwealth University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016350","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-47444-3","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T07:28:00Z","timestamp":1776670080000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A degrader of HER2 and EGFR abolishes p95HER2 and shows robust antitumor efficacy in HER2-positive breast cancer"],"prefix":"10.1038","volume":"16","author":[{"given":"Lu","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arup","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darrell","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuesheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"issue":"1","key":"47444_CR1","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1016\/j.clbc.2021.05.004","volume":"22","author":"R Memon","year":"2022","unstructured":"Memon, R. et al. Discordance between immunohistochemistry and in situ hybridization to detect HER2 overexpression\/gene amplification in breast cancer in the modern age: A single institution experience and pooled literature review study. Clin. Breast Cancer 22(1), e123\u2013e133 (2022).","journal-title":"Clin. Breast Cancer"},{"issue":"10","key":"47444_CR2","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1200\/OP.21.00172","volume":"17","author":"O Martinez-Saez","year":"2021","unstructured":"Martinez-Saez, O. & Prat, A. Current and future management of HER2-positive metastatic breast cancer. JCO Oncol. Pract. 17(10), 594\u2013604 (2021).","journal-title":"JCO Oncol. Pract."},{"issue":"2","key":"47444_CR3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","volume":"22","author":"SM Swain","year":"2023","unstructured":"Swain, S. M., Shastry, M. & Hamilton, E. Targeting HER2-positive breast cancer: Advances and future directions. Nat. Rev. Drug Discov. 22(2), 101\u2013126 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"47444_CR4","first-page":"347","volume":"8","author":"MA Molina","year":"2002","unstructured":"Molina, M. A. et al. NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. Clin. Cancer Res. 8(2), 347\u2013353 (2002).","journal-title":"Clin. Cancer Res."},{"issue":"16","key":"47444_CR5","doi-asserted-by":"publisher","first-page":"4226","DOI":"10.1158\/1078-0432.CCR-10-0410","volume":"16","author":"J Sperinde","year":"2010","unstructured":"Sperinde, J. et al. Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients. Clin. Cancer Res. 16(16), 4226\u20134235 (2010).","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"47444_CR6","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.1128\/MCB.01803-08","volume":"29","author":"K Pedersen","year":"2009","unstructured":"Pedersen, K. et al. A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis. Mol. Cell. Biol. 29(12), 3319\u20133331 (2009).","journal-title":"Mol. Cell. Biol."},{"issue":"5","key":"47444_CR7","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1158\/0008-5472.CAN-10-3795","volume":"71","author":"J Arribas","year":"2011","unstructured":"Arribas, J., Baselga, J., Pedersen, K. & Parra-Palau, J. L. p95HER2 and breast cancer. Cancer Res. 71(5), 1515\u20131519 (2011).","journal-title":"Cancer Res."},{"issue":"5","key":"47444_CR8","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1093\/annonc\/mdm585","volume":"19","author":"V Ludovini","year":"2008","unstructured":"Ludovini, V. et al. Evaluation of serum HER2 extracellular domain in early breast cancer patients: Correlation with clinicopathological parameters and survival. Ann. Oncol. 19(5), 883\u2013890 (2008).","journal-title":"Ann. Oncol."},{"issue":"3","key":"47444_CR9","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1158\/1078-0432.CCR-14-1824","volume":"21","author":"M Scaltriti","year":"2015","unstructured":"Scaltriti, M. et al. High HER2 expression correlates with response to the combination of lapatinib and trastuzumab. Clin. Cancer Res. 21(3), 569\u2013576 (2015).","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"47444_CR10","first-page":"5570","volume":"8","author":"O Segatto","year":"1988","unstructured":"Segatto, O., King, C. R., Pierce, J. H., Di Fiore, P. P. & Aaronson, S. A. Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene. Mol. Cell. Biol. 8(12), 5570\u20135574 (1988).","journal-title":"Mol. Cell. Biol."},{"issue":"22","key":"47444_CR11","first-page":"5123","volume":"58","author":"TA Christianson","year":"1998","unstructured":"Christianson, T. A. et al. NH2-terminally truncated HER-2\/neu protein: Relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res. 58(22), 5123\u20135129 (1998).","journal-title":"Cancer Res."},{"key":"47444_CR12","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13058-015-0624-x","volume":"17","author":"G Kallergi","year":"2015","unstructured":"Kallergi, G. et al. Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients. Breast Cancer Res. 17, 113 (2015).","journal-title":"Breast Cancer Res."},{"issue":"13","key":"47444_CR13","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1158\/1078-0432.CCR-17-1864","volume":"24","author":"S Chumsri","year":"2018","unstructured":"Chumsri, S. et al. High p95HER2\/HER2 ratio associated with poor outcome in trastuzumab-treated HER2-positive metastatic breast cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance). Clin. Cancer Res. 24(13), 3053\u20133058 (2018).","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"47444_CR14","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1158\/1078-0432.CCR-13-2782","volume":"20","author":"R Duchnowska","year":"2014","unstructured":"Duchnowska, R. et al. Quantitative measurements of tumoral p95HER2 protein expression in metastatic breast cancer patients treated with trastuzumab: independent validation of the p95HER2 clinical cutoff. Clin. Cancer Res. 20(10), 2805\u20132813 (2014).","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"47444_CR15","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1093\/jnci\/djk134","volume":"99","author":"M Scaltriti","year":"2007","unstructured":"Scaltriti, M. et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J. Natl. Cancer Inst. 99(8), 628\u2013638 (2007).","journal-title":"J. Natl. Cancer Inst."},{"issue":"7","key":"47444_CR16","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1038\/s43018-025-00969-4","volume":"6","author":"D Hu","year":"2025","unstructured":"Hu, D. et al. p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2(+) breast cancer that limits trastuzumab deruxtecan efficacy. Nat. Cancer 6(7), 1202\u20131222 (2025).","journal-title":"Nat. Cancer"},{"issue":"9","key":"47444_CR17","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1158\/1078-0432.CCR-09-3407","volume":"16","author":"M Scaltriti","year":"2010","unstructured":"Scaltriti, M. et al. Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor. Clin. Cancer Res. 16(9), 2688\u20132695 (2010).","journal-title":"Clin. Cancer Res."},{"key":"47444_CR18","doi-asserted-by":"publisher","first-page":"107677","DOI":"10.1016\/j.pharmthera.2020.107677","volume":"218","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y. The root cause of drug resistance in HER2-positive breast cancer and the therapeutic approaches to overcoming the resistance. Pharmacol. Ther. 218, 107677 (2021).","journal-title":"Pharmacol. Ther."},{"issue":"6","key":"47444_CR19","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1200\/JCO.2005.09.055","volume":"23","author":"MP DiGiovanna","year":"2005","unstructured":"DiGiovanna, M. P. et al. Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. J. Clin. Oncol. 23(6), 1152\u20131160 (2005).","journal-title":"J. Clin. Oncol."},{"key":"47444_CR20","doi-asserted-by":"publisher","first-page":"101078","DOI":"10.1016\/j.drup.2024.101078","volume":"74","author":"L Yang","year":"2024","unstructured":"Yang, L. et al. Targeted dual degradation of HER2 and EGFR obliterates oncogenic signaling, overcomes therapy resistance, and inhibits metastatic lesions in HER2-positive breast cancer models. Drug Resist. Updat. 74, 101078 (2024).","journal-title":"Drug Resist. Updat."},{"key":"47444_CR21","doi-asserted-by":"publisher","first-page":"e1211","DOI":"10.1038\/cddis.2014.187","volume":"5","author":"L Yang","year":"2014","unstructured":"Yang, L., Li, Y. & Zhang, Y. Identification of prolidase as a high affinity ligand of the ErbB2 receptor and its regulation of ErbB2 signaling and cell growth. Cell Death Dis. 5, e1211 (2014).","journal-title":"Cell Death Dis."},{"issue":"11","key":"47444_CR22","doi-asserted-by":"publisher","first-page":"dju291","DOI":"10.1093\/jnci\/dju291","volume":"106","author":"JL Parra-Palau","year":"2014","unstructured":"Parra-Palau, J. L. et al. Effect of p95HER2\/611CTF on the response to trastuzumab and chemotherapy. J. Natl. Cancer Inst. 106(11), dju291 (2014).","journal-title":"J. Natl. Cancer Inst."},{"issue":"7","key":"47444_CR23","doi-asserted-by":"publisher","first-page":"e6146","DOI":"10.1371\/journal.pone.0006146","volume":"4","author":"J Kao","year":"2009","unstructured":"Kao, J. et al. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS ONE 4(7), e6146 (2009).","journal-title":"PLoS ONE"},{"issue":"3","key":"47444_CR24","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0002-9440(10)64952-8","volume":"156","author":"TA Jarvinen","year":"2000","unstructured":"Jarvinen, T. A. et al. Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am. J. Pathol. 156(3), 839\u2013847 (2000).","journal-title":"Am. J. Pathol."},{"issue":"4","key":"47444_CR25","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1158\/1541-7786.MCR-08-0107","volume":"7","author":"X Hu","year":"2009","unstructured":"Hu, X. et al. Genetic alterations and oncogenic pathways associated with breast cancer subtypes. Mol. Cancer Res. 7(4), 511\u2013522 (2009).","journal-title":"Mol. Cancer Res."},{"issue":"3","key":"47444_CR26","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s10549-009-0592-x","volume":"122","author":"R Dua","year":"2010","unstructured":"Dua, R. et al. EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance. Breast Cancer Res. Treat. 122(3), 685\u2013697 (2010).","journal-title":"Breast Cancer Res. Treat."},{"issue":"476","key":"47444_CR27","doi-asserted-by":"publisher","first-page":"eaav1620","DOI":"10.1126\/scitranslmed.aav1620","volume":"11","author":"L Yang","year":"2019","unstructured":"Yang, L., Li, Y., Bhattacharya, A. & Zhang, Y. A recombinant human protein targeting HER2 overcomes drug resistance in HER2-positive breast cancer. Sci. Transl. Med. 11(476), eaav1620 (2019).","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"47444_CR28","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s13046-022-02389-z","volume":"41","author":"L Yang","year":"2022","unstructured":"Yang, L. et al. Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer. J. Exp. Clin. Cancer Res. 41(1), 184 (2022).","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"12","key":"47444_CR29","doi-asserted-by":"publisher","first-page":"e1000563","DOI":"10.1371\/journal.pbio.1000563","volume":"8","author":"M Gijsen","year":"2010","unstructured":"Gijsen, M. et al. HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 Herceptin in breast cancer. PLoS Biol. 8(12), e1000563 (2010).","journal-title":"PLoS Biol."},{"issue":"6","key":"47444_CR30","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1124\/pharmrev.123.000906","volume":"75","author":"Y Zhang","year":"2023","unstructured":"Zhang, Y. Targeting epidermal growth factor receptor for cancer treatment: Abolishing both kinase-dependent and kinase-independent functions of the receptor. Pharmacol. Rev. 75(6), 1218\u20131232 (2023).","journal-title":"Pharmacol. Rev."},{"issue":"12","key":"47444_CR31","first-page":"4744","volume":"61","author":"MA Molina","year":"2001","unstructured":"Molina, M. A. et al. Trastuzumab (Herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells. Cancer Res. 61(12), 4744\u20134749 (2001).","journal-title":"Cancer Res."},{"issue":"4","key":"47444_CR32","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/nm.2309","volume":"17","author":"S Zhang","year":"2011","unstructured":"Zhang, S. et al. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat. Med. 17(4), 461\u2013469 (2011).","journal-title":"Nat. Med."},{"issue":"4","key":"47444_CR33","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1158\/1535-7163.MCT-19-0873","volume":"19","author":"A Kulukian","year":"2020","unstructured":"Kulukian, A. et al. Preclinical activity of HER2-selective tyrosine kinase inhibitor tucatinib as a single agent or in combination with trastuzumab or docetaxel in solid tumor models. Mol. Cancer Ther. 19(4), 976\u2013987 (2020).","journal-title":"Mol. Cancer Ther."},{"issue":"10382","key":"47444_CR34","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/S0140-6736(23)00350-1","volume":"401","author":"TJ Craig","year":"2023","unstructured":"Craig, T. J. et al. Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401(10382), 1079\u20131090 (2023).","journal-title":"Lancet"},{"issue":"5","key":"47444_CR35","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ebiom.2015.03.016","volume":"2","author":"L Yang","year":"2015","unstructured":"Yang, L., Li, Y., Bhattacharya, A. & Zhang, Y. Inhibition of ERBB2-overexpressing tumors by recombinant human prolidase and its enzymatically inactive mutant. EBioMedicine 2(5), 396\u2013405 (2015).","journal-title":"EBioMedicine"},{"key":"47444_CR36","doi-asserted-by":"publisher","first-page":"114775","DOI":"10.1016\/j.ejmech.2022.114775","volume":"244","author":"M Hu","year":"2022","unstructured":"Hu, M. et al. Discovery of potent and selective HER2 PROTAC degrader based Tucatinib with improved efficacy against HER2 positive cancers. Eur. J. Med. Chem. 244, 114775 (2022).","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"47444_CR37","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1080\/17568919.2025.2463871","volume":"17","author":"NC Rallabandi","year":"2025","unstructured":"Rallabandi, N. C., Panpatil, D., Gahtory, D., Navik, U. & Kumar, R. EGFR molecular degraders: Preclinical successes and the road ahead. Future Med. Chem. 17(6), 633\u2013636 (2025).","journal-title":"Future Med. Chem."},{"issue":"1","key":"47444_CR38","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.chembiol.2017.09.009","volume":"25","author":"GM Burslem","year":"2018","unstructured":"Burslem, G. M. et al. The Advantages of targeted protein degradation over inhibition: an RTK case study. Cell Chem. Biol. 25(1), 67\u201377 (2018).","journal-title":"Cell Chem. Biol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47444-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47444-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47444-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T15:11:29Z","timestamp":1776697889000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47444-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["47444"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-47444-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"assertion":[{"value":"4 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All mouse experiments were carried out under protocol AD10003095 approved by the Institutional Animal Care and Use Committee (IACUC) at Virginia Commonwealth University. All experiments were performed in accordance with relevant guidelines and regulations. The ARRIVE guidelines have been carefully followed during the course of this study. Maximal tumor size permitted by the IACUC is 2000 mm\n                      3\n                      , and mice were euthanized by carbon dioxide inhalation once their tumors reached the upper size limit.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"We confirm that this work is original and has not been published elsewhere, nor is it currently under consideration for publication elsewhere. All authors approve the publication of this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12890"}}